These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 422224)

  • 1. Multiple effects of a diamidine (propamidine) on complement activation.
    Vogt W; Hinsch B; Schmidt G; Von Zabern I
    Immunology; 1979 Jan; 36(1):131-7. PubMed ID: 422224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
    Vogt W; Schmidt G; Hinsch B
    Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the classical complement pathway by nephritic factor bound to the alternative pathway C3/C5 convertase.
    Sobel AT; Cooper NR; Schreiber RD
    J Immunol; 1979 Jan; 122(1):34-8. PubMed ID: 762421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of the alternative pathway of human complement in vitro by a natural microbial product, complestatin.
    Kaneko I; Fearon DT; Austen KF
    J Immunol; 1980 Mar; 124(3):1194-8. PubMed ID: 6898640
    [No Abstract]   [Full Text] [Related]  

  • 9. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.
    Fries LF; Friedman HM; Cohen GH; Eisenberg RJ; Hammer CH; Frank MM
    J Immunol; 1986 Sep; 137(5):1636-41. PubMed ID: 3018078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a streptococcal preparation on the complement system.
    Kato H; Yokoe N; Matsumura N; Nishida K; Ikezaki M; Hosokawa K; Hotta T; Takemura S; Yoshikawa T; Kondo M
    Jpn J Exp Med; 1979 Oct; 49(5):343-50. PubMed ID: 529490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro inhibition of the classical pathway of human complement by a natural microbial product, colistin sulphate.
    Asghar SS; de Koster A; van der Helm HJ
    Biochem Pharmacol; 1986 Sep; 35(17):2917-21. PubMed ID: 3638137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
    Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
    Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of a new non-steroid anti-inflammatory drug, carprofen (Ro 20-5720) on activation of the complement system: an in vitro research.
    Auteria A; Laghi Pasini F; Di Perri T
    Int J Tissue React; 1982; 4(1):9-13. PubMed ID: 7085003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of plicatic acid on human serum complement includes interference with C1 inhibitor function.
    Giclas PC
    J Immunol; 1982 Jul; 129(1):168-72. PubMed ID: 6979566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement component C2, inhibiting a latent serine protease in the classical pathway of complement activation.
    Halili MA; Ruiz-Gómez G; Le GT; Abbenante G; Fairlie DP
    Biochemistry; 2009 Sep; 48(35):8466-72. PubMed ID: 19642650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement activating property of the protein-rich endotoxin (OEP) of Pseudomonas aeruginosa. I. Activation of both the classical and the alternative pathways of guinea pig complement.
    Inada K
    Jpn J Exp Med; 1980 Feb; 50(1):13-21. PubMed ID: 6770130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteases in complement system (author's transl)].
    Nagasawa S
    Tanpakushitsu Kakusan Koso; 1980; 25(6):531-46. PubMed ID: 7010425
    [No Abstract]   [Full Text] [Related]  

  • 19. Relative resistance of the F-42-stabilized classical pathway C3 convertase to inactivation by C4-binding protein.
    Daha MR; van Es LA
    J Immunol; 1980 Nov; 125(5):2051-4. PubMed ID: 6903579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
    Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
    J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.